Patent Tracker

Subject Matter

Methods for treatment for patients suffering from disease or condition are contemplated as including an administration of an intravenous infusion of a pharmaceutically effective amount of psilocybin or psilocin. The intravenous infusion of psilocybin or psilocin may include an additional compound such as a benzodiazepine, preferably lorazepam, administered via a continuous intra-venous infusion. Such methods may be seen to better alleviate the symptoms of psychological conditions, neurological injuries, pain, or inflammatory condition, and may result in reduced need for other medications.

Subject Matter

A novel class ofMDMA carbamates that can be activated in vivo as prodrugs. The MDMA prodrugs of the invention are enzymatically cleaved in vivo and produce alcohols of low toxicity that are well tolerated and metabolized in humans.

Subject Matter

The use of entheogens to treat psychiatric disorders, brain injuries, and autism, and in particular to the use of entheogens to treat obsessive compulsive disorder (OCD), schizophrenia, depression, post-traumatic stress disorder (PTSD), anxiety, autism spectrum disorder, traumatic brain injury (TBI), concussion, and chronic traumatic encephalopathy (CTE).

Subject Matter

Provided herein is a process for the preparation of (R)-3,4 methylenedioxymethamphetamine HCl Form 1.

Subject Matter

Methods for treating a subject in need thereof comprising administering to the subject a therapeutically-effective dose of psilocybin. The methods described herein may be used to treat a variety of diseases, disorders, and conditions. For example, the methods may be used to treat anxiety disorders, eating disorders, and headache disorders.

Subject Matter

Novel multi-substituent psilocybin derivative compounds and pharmaceutical and recreational drug formulations containing the same. The compounds may be produced by reacting a reactant psilocybin derivative with a substituent containing compound.

Subject Matter

Invention is directed to novel chemical compositions of matter and their methods of synthesis, and in particular novel analogs of Psilocin having enhanced physical and pharmacokinetic characteristics.

Subject Matter

Mushroom compositions and methods for treating, prophylaxis of, or ameliorating symptoms of one or more adverse reactions triggered by an infectious disease or condition that increases an anti-inflammatory response in a subject with such compositions. In one aspect the composition comprises an aqueous or solid fraction of a mycelium, a fermented substrate thereof, or a combination thereof optionally combined with one or more buffering agents, ethanol, and water.

Subject Matter

Certain therapeutic substituted heterocyclic bridged ring compounds, including substituted morpholine, thiomorpholine, and piperidine compounds and their homologues, having various advantages over current compounds used in certain methods of drug-assisted therapy, such as MDMA, together with pharmaceutical compositions containing such compounds, and methods of their use to treat mental health disorders and CNS disorders.

Subject Matter

Salt and solid forms of tabernanthalog. Disclosed solid forms may be a polymorph of tabernanthalog fumarate, and/or may have improved properties, such as improved physical, chemical and/or pharmacokinetic properties. Disclosed salts include pharmaceutically acceptable salts of tabernanthalog. Disclosed solid forms include free base and salt forms of tabernanthalog, including amorphous and crystalline forms of tabernanthalog, such as tabernanthalog free base or a salt thereof. Also disclosed are methods for making the salts and solid forms and methods for administering the same. The salt and solid forms of tabernanthalog and salts thereof are useful for treating neurological disease and/or a psychiatric disorder in a subject.